The present invention is directed to compositions regarding a specific
mutation in estrogen receptor alpha and their use as diagnostic markers
in breast tissue, such as premalignant lesions, for the development of
breast cancer. More specifically, cells of breast cancer whose nucleic
acid comprises the estrogen receptor alpha mutation identify the breast
cancer to be an invasive breast cancer.